[go: up one dir, main page]

WO2009049098A3 - Materials and methods for regulating the activity of phosphatases - Google Patents

Materials and methods for regulating the activity of phosphatases Download PDF

Info

Publication number
WO2009049098A3
WO2009049098A3 PCT/US2008/079426 US2008079426W WO2009049098A3 WO 2009049098 A3 WO2009049098 A3 WO 2009049098A3 US 2008079426 W US2008079426 W US 2008079426W WO 2009049098 A3 WO2009049098 A3 WO 2009049098A3
Authority
WO
WIPO (PCT)
Prior art keywords
phosphatases
activity
regulating
materials
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/079426
Other languages
French (fr)
Other versions
WO2009049098A2 (en
Inventor
Zhong-Yin Zhang
Yantao He
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indiana University Research and Technology Corp
Original Assignee
Indiana University Research and Technology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indiana University Research and Technology Corp filed Critical Indiana University Research and Technology Corp
Publication of WO2009049098A2 publication Critical patent/WO2009049098A2/en
Publication of WO2009049098A3 publication Critical patent/WO2009049098A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Reported herein are bidentate or tridentate salicylic acid based combinatorial libraries and method of making and using the same to inhibit phosphatases. Generally, these inhibitors include elements that interact with both the active site and a nearby peripheral site of phosphates such as Lyp, SHP2 and mPTPB. These moleuces are used to study, characterize, regulate and inhibit various phosphatases. These molecules and pharmaceutically acceptable salts of them may be use to treat various diseases or conditions that involve the activity of at least one phosphatase.
PCT/US2008/079426 2007-10-09 2008-10-09 Materials and methods for regulating the activity of phosphatases Ceased WO2009049098A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97860307P 2007-10-09 2007-10-09
US60/978,603 2007-10-09

Publications (2)

Publication Number Publication Date
WO2009049098A2 WO2009049098A2 (en) 2009-04-16
WO2009049098A3 true WO2009049098A3 (en) 2009-05-28

Family

ID=40549839

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/079426 Ceased WO2009049098A2 (en) 2007-10-09 2008-10-09 Materials and methods for regulating the activity of phosphatases

Country Status (1)

Country Link
WO (1) WO2009049098A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012149048A1 (en) * 2011-04-26 2012-11-01 Indiana University Research And Technology Corporation Tyrosine phosphatase inhibitors and uses thereof to modulate the activity of lyp
EP2848612B1 (en) * 2012-05-08 2017-07-19 Ishihara Sangyo Kaisha, Ltd. Method for producing a substituted benzoic acid compound
CN104311526B (en) * 2014-09-13 2016-03-23 中山大学 Binaphthyl derivatives derived from marine fungi, their preparation methods and their application in anti-tuberculosis
CN104311525A (en) * 2014-09-13 2015-01-28 中山大学 Use of marine fungus-derived Azaphilone compound in preparation of antituberculosis drugs
JP6925265B2 (en) * 2014-09-16 2021-08-25 エスアールアイ インターナショナルＳＲＩ Ｉｎｔｅｒｎａｔｉｏｎａｌ Discovery of Affinity Reagents and Catalysts by Fiber Optic Array Scanning Technology The present invention was made with national treasury assistance under Contract No. N66601-14-C-4059 awarded by Space and Naval Warfare Systems Command Systems Center Pacific. Government has certain rights with respect to the present invention.
WO2018045182A1 (en) * 2016-09-01 2018-03-08 The Board Of Regents Of Hte University Of Texas System Disubstituted and trisubtituted 1,2,3-triazoles as wnt inhibitors
TW201940167A (en) 2018-03-21 2019-10-16 美商新標利亞治療藥物公司 SHP2 inhibitors and uses thereof
AU2020232242A1 (en) 2019-03-01 2021-09-09 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
CN113727758A (en) 2019-03-01 2021-11-30 锐新医药公司 Bicyclic heterocyclic compounds and use thereof
WO2021091982A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
CN120699039A (en) 2019-11-04 2025-09-26 锐新医药公司 RAS inhibitors
BR112022008535A2 (en) 2019-11-04 2022-08-09 Revolution Medicines Inc COMPOUND, PHARMACEUTICAL COMPOSITION, METHODS TO TREAT CANCER AND A RAS PROTEIN DISORDER
US20210139517A1 (en) 2019-11-08 2021-05-13 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
JP2023505100A (en) 2019-11-27 2023-02-08 レボリューション メディシンズ インコーポレイテッド Covalent RAS inhibitors and uses thereof
AU2021306571A1 (en) * 2020-07-06 2023-01-19 Centre Leon Berard Indole derivatives and uses thereof for treating a cancer
JP2024501280A (en) 2020-12-22 2024-01-11 キル・レガー・セラピューティクス・インコーポレーテッド SOS1 inhibitors and their uses
WO2024243441A1 (en) 2023-05-24 2024-11-28 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
WO2025137507A1 (en) 2023-12-22 2025-06-26 Regor Pharmaceuticals, Inc. Sos1 inhibitors and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020119501A1 (en) * 1997-05-20 2002-08-29 Bahija Jallal Diagnosis and treatment of PTP04 related disorders
US6596772B1 (en) * 1999-08-27 2003-07-22 Sugen, Inc. Phosphate mimics and methods of treatment using phosphatase inhibitors
US7005445B2 (en) * 2001-10-22 2006-02-28 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors and methods for designing them

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020119501A1 (en) * 1997-05-20 2002-08-29 Bahija Jallal Diagnosis and treatment of PTP04 related disorders
US6596772B1 (en) * 1999-08-27 2003-07-22 Sugen, Inc. Phosphate mimics and methods of treatment using phosphatase inhibitors
US7005445B2 (en) * 2001-10-22 2006-02-28 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors and methods for designing them

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YU ET AL.: "Structure, inhibitor, and regulatory mechanism of Lyp, a lymphoid-specific tyrosine phosphatase implicated in autoimmune diseases.", PROC. NATL. ACAD. SCI., vol. 104, no. 50, 11 December 2007 (2007-12-11), USA, pages 19767 - 19772 *

Also Published As

Publication number Publication date
WO2009049098A2 (en) 2009-04-16

Similar Documents

Publication Publication Date Title
WO2009049098A3 (en) Materials and methods for regulating the activity of phosphatases
WO2014033447A3 (en) Diaryl urea derivatives as p38 map kinase inhibitors
MX2009011951A (en) Compounds and compositions as c-kit and pdgfr kinase inhibitors.
EA201490545A1 (en) COMPOUNDS AND COMPOSITIONS AS KINASE C-Kit KINASE INHIBITORS
MX2010009207A (en) Heterocyclic compounds and compositions as c-kit and pdgfr kinase inhibitors.
EP2576549A4 (en) Bicyclic Heteroarylkinase Inhibitors and Methods of Use
WO2011014795A3 (en) Compounds and compositions as syk kinase inhibitors
MX2009011952A (en) Compounds and compositions as c-kit and pdgfr kinase inhibitors.
MX342873B (en) Substituted pyrazolo-quinazoline derivatives as kinase inhibitors.
WO2013119946A8 (en) Long chain base sphingosine kinase inhibitors
WO2008132434A3 (en) 4-aza indole derivatives and their use as fungicides
BRPI0811617A2 (en) primidine derivatives and compositions as c-kit and pdgfr kinase inhibitors.
WO2014066486A3 (en) Biomarker for use in treating anemia
MX2013004491A (en) Boronates as arginase inhibitors.
WO2009042962A3 (en) Antidotes for factor xa inhibitors and methods of using the same
CU20140023A7 (en) DERIVATIVES OF N- (3- (1,2,4-OXADIAZOL-3/5-IL) PHENYL) IMIDAZO [1,2-a] PIRIDIN-3-CARBOXAMIDE AS INHIBITORS OF KINASE C-Kit
IN2014MN02497A (en)
MX2013012981A (en) Substituted indazole derivatives active as kinase inhibitors.
WO2012037155A3 (en) Tyrosine kinase inhibitors
WO2012065958A9 (en) Method of treating contrast-induced nephropathy
WO2012034055A3 (en) Compounds as c-met kinase inhibitors
WO2011149288A3 (en) Anti-inflammatory compound having inhibitory activity against multiple tyrosine kinases, and pharmaceutical composition containing same
WO2008097546A3 (en) Compounds that inhibit cholinesterase
EP4389225A3 (en) Cancer treatments using combinations of type 2 mek and erk inhibitors
WO2008083160A3 (en) Methods and compositions for therapeutic treatment

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08838464

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08838464

Country of ref document: EP

Kind code of ref document: A2